Researchers analyzed data from several clinical trials involving 101 patients with advanced head and neck cancer. These patients were treated with a group of medications known as Histone Deacetylase Inhibitors (HDACi). This includes specific drugs like Vorinostat, valproic acid, panobinostat, and romidepsin.
The analysis found that about 65 percent of the patients showed a favorable response to the HDACi therapy. When these drugs were used alongside chemotherapy, chemoradiotherapy, or targeted therapy, the response rate was even higher, reaching about 76 percent. For patients who had already received prior treatments, the response rate was about 49 percent.
Because this study combined data from several small, single-arm trials, the results should be viewed with caution. There was no specific data provided regarding side effects or how well patients tolerated the drugs. These findings suggest that HDAC inhibitors could be a helpful addition to current treatments for advanced head and neck cancer, but more large-scale studies are needed to confirm these results.
